不同评分系统评估慢性粒细胞白血病患者预后的比较

论文摘要

目的:比较现有预后评分系统在新诊断的慢性粒细胞白血病（chronic myeloid leukemia,CML）患者中预测疗效及预后的有效性。识别治疗反应率和生存率明显较低的CML患者,有利于进行早期干预。进一步评估ELTS评分作为预测"CML相关性死亡发生率"这一新指标的能力。方法:回顾性分析2010年1月至2019年12月连云港市第一人民医院确诊并接受一线伊马替尼治疗的172例慢性粒细胞白血病慢性期（chronic myeloid leukemia-chronic phase,CML-CP）患者,采用Sokal、Hasford、EUTOS及ELTS评分,将患者分为各个风险组并比较各评分系统对CML患者总生存期（overall survival,OS）、无进展生存期（progression free survival,PFS）、主要分子学反应（major molecular response,MMR）及与CML相关性死亡发生率等治疗效果和随访评估的作用。结果:在172例患者中,EUTOS及ELTS评分系统能较好地预测MMR的累积发生率（P<0.001,P=0.015）、OS（P<0.001,P=0.001）和PFS（P<0.001,P<0.001）。但是,Sokal和Hasford评分均未能预测伊马替尼治疗CML-CP的反应和结果（均P>0.05）。ELTS评分在因CML导致相关性死亡方面,差异具有统计学意义（P<0.010）,而Sokal、Hasford和EUTOS评分系统均未见显著性差异（P=0.07,P=0.10,P=0.08）,与其他3项预后评分相比,ELTS评分在预测与CML相关性死亡方面具有更高的准确性。结论:在预测伊马替尼治疗的CML患者的结局方面,EUTOS、ELTS评分系统优于Sokal、Hasford评分。新的ELTS评分可以对一线伊马替尼治疗CML患者的长期抗白血病疗效进行更好地前瞻性评估。

论文目录

文章来源

类型: 期刊论文

作者: 贾茜婷,毛建平,薛连国,蔡志梅,赵利东

关键词: 慢性粒细胞白血病,伊马替尼,评分

来源: 中国肿瘤临床 2019年24期

年度: 2019

分类: 医药卫生科技

专业: 肿瘤学

单位: 南京医科大学连云港临床医学院连云港市第一人民医院血液科

基金: 连云港市卫生计生科技项目（编号：201711）资助~~

分类号: R733.72

页码: 1265-1270

总页数: 6

文件大小: 1531K

下载量: 42

相关论文文献

• [1].Effective targets identified for myeloid leukemia treatment[J]. Science Foundation in China 2019(04)
• [2].Expression of Tim-3 on natural killer cells in patients with acute myeloid leukemia and its clinical significance[J]. China Medical Abstracts(Internal Medicine) 2019(04)
• [3].Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics[J]. China Medical Abstracts(Internal Medicine) 2020(01)
• [4].Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase[J]. China Medical Abstracts(Internal Medicine) 2020(02)
• [5].The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia[J]. The Journal of Biomedical Research 2016(06)
• [6].Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the chronic phase[J]. China Medical Abstracts(Internal Medicine) 2017(01)
• [7].EVI1 expression,clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia[J]. China Medical Abstracts(Internal Medicine) 2017(01)
• [8].Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase[J]. China Medical Abstracts(Internal Medicine) 2017(01)
• [9].A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients' perspective[J]. China Medical Abstracts(Internal Medicine) 2016(03)
• [10].Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase[J]. China Medical Abstracts(Internal Medicine) 2019(03)
• [11].The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts[J]. China Medical Abstracts(Internal Medicine) 2017(04)
• [12].Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience[J]. World Journal of Hematology 2017(01)
• [13].A comparison of efficacy and safety between Chinese generic imatinib and branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase:a single-center prospective cohort study[J]. China Medical Abstracts(Internal Medicine) 2017(01)
• [14].Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia[J]. China Medical Abstracts(Internal Medicine) 2013(02)
• [15].Expression level of CDX2 gene in acute myeloid leukemia and its clinical significance[J]. China Medical Abstracts(Internal Medicine) 2012(04)
• [16].Expression characteristics and prognosissignificance of miRNA-181a in acute myeloid leukemia with normal karyotype[J]. China Medical Abstracts(Internal Medicine) 2017(04)
• [17].Effects of NPM1 gene expression on acute myeloid leukemia cell lines and its mechanism[J]. China Medical Abstracts(Internal Medicine) 2018(01)
• [18].The clinical analysis of haploidentical stem cell transplantation in myelodysplastic syndrome-associated acute myeloid leukemia[J]. China Medical Abstracts(Internal Medicine) 2018(03)
• [19].20-Hydroxyecdysone from Dacrycarpus imbricatus bark inhibits the proliferation of acute myeloid leukemia cells[J]. Asian Pacific Journal of Tropical Medicine 2017(02)
• [20].Gastric myeloid sarcoma without acute myeloblastic leukemia[J]. World Journal of Gastroenterology 2015(07)
• [21].Regulator of myeloid differentiation and function:The secret life of Ikaros[J]. World Journal of Biological Chemistry 2011(06)
• [22].Molecular landscape in acute myeloid leukemia: where do we stand in 2016[J]. Cancer Biology & Medicine 2016(04)
• [23].The expression of PML in chronic myeloid leukemia and effect on cell proliferation[J]. China Medical Abstracts(Internal Medicine) 2013(03)
• [24].Characterization of functional transposable element enhancers in acute myeloid leukemia[J]. Science China(Life Sciences) 2020(05)
• [25].Factors associated with early treatment response in adults with acute myeloid leukemia[J]. China Medical Abstracts(Internal Medicine) 2017(04)
• [26].Cytogentic and prognostic characteristic of acute myeloid leukemia with monosomal karyotype[J]. China Medical Abstracts(Internal Medicine) 2016(03)
• [27].NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions[J]. Science China(Life Sciences) 2015(12)
• [28].Feasibility of iFISH patterns in hematologic malignancies among Congolese patients at Kinshasa University clinics[J]. Asian Pacific Journal of Tropical Biomedicine 2017(12)
• [29].Murine models based on acute myeloid leukemia-initiating stem cells xenografting[J]. World Journal of Stem Cells 2018(06)
• [30].Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies[J]. World Journal of Clinical Oncology 2018(05)

标签：慢性粒细胞白血病论文;  伊马替尼论文;  评分论文;